Vaccines are over-formulated to protect against potency loss

Vaccines start with the isolation of chemically defined media, but they come into being during formulation. The delicate development process stabilizes the separate components into a uniform mixture and prepares it for batch dosing. Cell cultures are often used in the development as well as formulation of Vaccines and has been that way for decades.

When it comes to producing vaccines, mixtures are typically over-formulated above the required potency. This method lowers yield but compensates for any possible degradation throughout the vaccine’s shelf-life.

Chromatography technology and mRNA techniques promise more accessible vaccines

Purification of the reaction mixture remains a challenge for large-scale vaccine development and production. But chromatography is emerging as an ideal purification technique for several biopharmaceuticals.  Ligands in the chromatography columns form ‘hooks’ that filter out specific contaminants.

Vaccine manufacturers are taking advantage of this purification technique to reduce vaccine production’s financial and environmental costs. This method is attracting particular interest with the development of mRNA vaccines to combine a relatively simple manufacturing process with the high-yield capabilities of chromatography.

Packaging is a crucial step in vaccine production. This step is often forgotten about but is important in ensuring that the vaccines reach their final destination without getting damaged. But more importantly, safe packing means that the vaccines will reach patients without getting contaminated.